• 1
    Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317.
  • 2
    Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver transplantation. Transplantation 1998; 66: 1612.
  • 3
    Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 2003; 9: 897.
  • 4
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
  • 5
    Ghobrial RM, Farmer DG, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229: 824; discussion 831.
  • 6
    Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3: 130.
  • 7
    Doyle HR, Morelli F, McMichael J, et al. Hepatic retransplantation: an analysis of risk factors associated with outcome. Transplantation 1996; 61: 1499.
  • 8
    Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29: 365.
  • 9
    Brown RS Jr, Kumar KS, Russo MW, et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002; 8: 278.
  • 10
    Neuhaus P, Langrehr JM, Williams R, Calne RY, Pichlmayr R, McMaster P. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. Transpl Int 1997; 10(4): 25361.
  • 11
    Langrehr JM, Nussler NC, Neumann U, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997; 63: 1772.
  • 12
    Anonymous. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
  • 13
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513.
  • 14
    Neumann UP, Neuhaus P. Discussion on spontaneous resolution of chronic hepatitis C virus after withdrawal of immunosuppression. Gastroenterology 2004; 126: 627.
  • 15
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: 28.
  • 16
    Roayaie S, Schiano TD, Thung SN, et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003; 38: 1428.
  • 17
    Sheiner PA. Retransplantation for hepatitis C: should it be performed? Yes. Liver Transpl Surg 1997; 3(5 Suppl. 1): S18.
  • 18
    Rosen HR. Retransplantation for hepatitis C: implications of different policies. Liver Transpl 2000; 6(6 Suppl. 2): S41 (Review).
  • 19
    Neff GW, O'Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10: 1497.
  • 20
    Spivak LJ. The blood system disorders. Lancet 2000; 355: 1707.
  • 21
    Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002; 35: 947.
  • 22
    Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533.
  • 23
    Prieto M, Nicolas D, Rayon JM, Berenguer M, Carrasco D, Mir J. Donor recipient HLA matching does not predict accelerated progression of hepatitis C after liver transplantation in genotyp 1b infection [abstract]. Hepatology 2000; 32: 261.
  • 24
    Neumann UP, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2b plus ribavarin. Transplantation 2006; 82: 43.
  • 25
    Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transpl Int 2005; 17: 759.